Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Annals of hematology - 1 Dec 2004

Dai Ming-Shen, Chao Tsu-Yi, Kao Woei-Yau, Shyu Rong-Yaun, Liu Tan-Mei

Abstract excerpt

Preemptive lamivudine in lymphoma patients undergoing intensive chemotherapy can effectively prevent chemotherapy-related HBV reactivation. Nevertheless, the safety profile after withdrawal of lamivudine and the impact of rituximab-containing chemotherapy on HBV reactivation has not been defined. To illustrate the necessity of prolonged surveillance after cessation of preemptive lamivudine in lymphoma patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Cyclophosphamide

Share to Prednisone

Share to Rituximab

Share to Vincristine

Share to Virus Activation

Source

Identifiers

PMID: 15338194
DOI: 10.1007/s00277-004-0899-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.PMID 15338194Read ↗

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.Semantic proximity Read ↗

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.Semantic proximity Read ↗

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.Semantic proximity Read ↗

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.Semantic proximity Read ↗

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.Semantic proximity Read ↗

Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Semantic proximity Read ↗

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.Semantic proximity Read ↗

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.Semantic proximity Read ↗

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.